Ren Wen-Lu, Yao Zhong-Wei, Ding Xiang-Wei, Jia Hui-Tian, Pan Ling-Hui, Chu Ming, Zhu He
Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China.
Phase I Clinical Research Center, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.
Compr Physiol. 2026 Feb;16(1):e70093. doi: 10.1002/cph4.70093.
Atrial fibrillation (AF) is one of the most common arrhythmias with complex pathogenesis. Recent studies showed that gut microbiota and its metabolic products, especially short-chain fatty acids (SCFAs), are closely linked to the onset and progression of AF. In this review, the alterations about SCFAs in AF patients were primarily summarized, and the potential mechanisms of SCFAs on the onset and progression of AF were further outlined. For the alterations, the contents of SCFAs in the circulatory system of AF patients were reduced, mainly ascribed to the dysregulation of SCFAs-producing gut microbiota and/or the reduction of genetic expression involved in the synthesis of SCFAs in the gut microbiota. For the potential mechanisms, SCFAs alleviate AF by inhibiting inflammation, relieving endoplasmic reticulum (ER) stress, mitigating oxidative stress, and improving atrial remodeling. Specifically, (1) SCFAs suppress inflammatory responses in AF mainly via activating GPCR, inhibiting the NLRP3 inflammasome, inhibiting HDAC activity, regulating vascular endothelial function, and maintaining gut barrier integrity. (2) SCFAs relieve ER stress in AF by reducing the expression of ER stress markers pPERK and/or CHOP, and correct ion current and calcium homeostasis disorders caused by TMAO. (3) SCFAs mitigate oxidative stress in AF by reducing mitochondrial damage and regulating Nrf2 pathways. (4) SCFAs improve atrial remodeling in AF by alleviating atrial structural and electrical remodeling. This review explores the regulatory mechanisms of SCFAs in alleviating AF from the gut-heart axis perspective, providing novel insights into AF prevention and treatment strategies.
心房颤动(AF)是最常见的心律失常之一,其发病机制复杂。最近的研究表明,肠道微生物群及其代谢产物,尤其是短链脂肪酸(SCFAs),与AF的发生和发展密切相关。在这篇综述中,主要总结了AF患者中SCFAs的变化,并进一步概述了SCFAs在AF发生和发展中的潜在机制。关于这些变化,AF患者循环系统中SCFAs的含量降低,主要归因于产生SCFAs的肠道微生物群失调和/或肠道微生物群中参与SCFAs合成的基因表达减少。关于潜在机制,SCFAs通过抑制炎症、减轻内质网(ER)应激、减轻氧化应激和改善心房重构来缓解AF。具体而言,(1)SCFAs主要通过激活GPCR、抑制NLRP3炎性小体、抑制HDAC活性、调节血管内皮功能和维持肠道屏障完整性来抑制AF中的炎症反应。(2)SCFAs通过降低ER应激标志物pPERK和/或CHOP的表达以及纠正由TMAO引起的离子电流和钙稳态紊乱来缓解AF中的ER应激。(3)SCFAs通过减少线粒体损伤和调节Nrf2途径来减轻AF中的氧化应激。(4)SCFAs通过减轻心房结构和电重构来改善AF中的心房重构。本综述从肠-心轴角度探讨了SCFAs在缓解AF中的调节机制,为AF的预防和治疗策略提供了新的见解。